Breast Cancer in Men (2003)

Letters19 August 2003Breast Cancer in MenSharon H. Giordano, MD, Aman U. Buzdar, MD, and Gabriel N. Hortobagyi, MDSharon H. Giordano, MDUniversity of Texas M.D. Anderson Cancer Center; Houston, TX 77030 (Giordano, Buzdar, Hortobagyi)Search for more papers by this author, Aman U. Buzdar, MDUniversity of Texas M.D. Anderson Cancer Center; Houston, TX 77030 (Giordano, Buzdar, Hortobagyi)Search for more papers by this author, and Gabriel N. Hortobagyi, MDUniversity of Texas M.D. Anderson Cancer Center; Houston, TX 77030 (Giordano, Buzdar, Hortobagyi)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-139-4-200308190-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate Dr. Jackson's interest in our article and will address his questions with pleasure. First, with regard to the role of sentinel lymph node biopsy in men, limited data are available. Several case reports of sentinel node biopsies performed in men have been published (1). However, the correlation between sentinel node biopsy and standard axillary dissection has not been established in men. We recognize that the rarity of male breast cancer makes the collection of a sufficient number of cases difficult, and thus it may not be possible to conclusively answer this question. Given that we would ...References1. Hill AD, Borgen PI, Cody HS. Sentinel node biopsy in male breast cancer. Eur J Surg Oncol. 1999;25:442-3. [PMID: 10419720] CrossrefMedlineGoogle Scholar2. Kim IY, Kim BC, Seong do H, Lee DK, Seo JM, Hong YJ, . Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 2002;62:5365-9. [PMID: 12235008] MedlineGoogle Scholar3. Liang Y, Eid MA, El Etreby F, Lewis RW, Kumar MV. Mifepristone-induced secretion of transforming growth factor beta1-induced apoptosis in prostate cancer cells. Int J Oncol. 2002;21:1259-67. [PMID: 12429976] MedlineGoogle Scholar4. Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, . Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res. 1995;55:5621-7. [PMID: 7585644] MedlineGoogle Scholar5. Steiner MS, Raghow S, Neubauer BL. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology. 2001;57:68-72. [PMID: 11295598] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Sharon H. Giordano, MD; Aman U. Buzdar, MD; Gabriel N. Hortobagyi, MDAffiliations: University of Texas M.D. Anderson Cancer Center; Houston, TX 77030 (Giordano, Buzdar, Hortobagyi) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBreast Cancer in Men Sharon H. Giordano , Aman U. Buzdar , and Gabriel N. Hortobagyi Breast Cancer in Men Robert H. Jackson Metrics 19 August 2003Volume 139, Issue 4Page: 305KeywordsBiopsyBreast cancerClinical epidemiologyClinical trialsEstrogensPositron emission tomographyProstate cancerRat modelsSentinel lymph nodeVesicles ePublished: 19 August 2003 Issue Published: 19 August 2003 Copyright & PermissionsCopyright © 2003 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...